glp 1 drugs gila monster venom How a Canadian scientist and a venomous lizard helped pave the way for Ozempic The history of GLP-1 therapeutics

Leiter LA, Bain SC, Hramiak I, Jodar E, Madsbad S, Gondolf T, et al

Briefly, FFAs can reduce the tyrosine phosphorylation of insulin receptor substrate-1 by activating the serine/threonine kinase, thereby aggravating IR (151)

Oury C, Marechal P, Donis N, Hulin A, Hego A, Tridetti J, et al

An increase in oxidative stress and ROS production play a role in mitochondrial DNA damage, respiratory impairment, and calcium imbalance, where all these symptoms of mitochondrial dysfunction are associated with AD

doi: 10.2337/db13-1440 28 HadjiyanniIBaggioLLPoussierPDruckerDJ

In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption